FDA Approves Enhertu® for Hormone Receptor-Positive, HER2-Low or HER2-Ultralow MBC
In December 2019, the US Food and Drug Administration (FDA) originally approved trastuzumab deruxtecan (Enhertu®), an antibody drug conjugate (ADC), for people...
Read More